Aldeyra Therapeutics to Provide Update on Late-Stage Clinical Development Pipeline at 2020 Research & Development Day
Aldeyra Therapeutics, Inc. (ALDX)
Last aldeyra therapeutics, inc. earnings: 11/7 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.aldeyra.com/investor-relations
Company Research
Source: Business Wire
Primary Endpoint of Symptom Control Achieved in Phase 2 Dry Eye Disease Formulation Clinical TrialStatistically Significant Combined Data Across Multiple Dry Eye Disease Clinical Trials Suggests Potential Early and Potent Activity in Signs and SymptomsIn Head-to-Head Clinical Trial, Tolerability of Reproxalap Superior to that of Xiidra® in Dry Eye Disease Patients over One Hour After InstillationLeading Ocular Surface Disease Expert Dr. Paul Karpecki to Highlight Treatment Challenges in Allergic Conjunctivitis and Dry Eye DiseaseLive Webcast Scheduled to Begin at Noon ET Today LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today will host the 2020 Research & Development Day (R&D Day) with investors and financial analysts in New York City to present recent clinical development updates and market opportunities for its novel investigational new drug product candidates in dry eye disease, allergic conjunctivitis, and proliferative vitreoretinopa
Show less
Read more
Impact Snapshot
Event Time:
ALDX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALDX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALDX alerts
High impacting Aldeyra Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ALDX
News
- Aldeyra Therapeutics to Participate in the Jefferies London Healthcare ConferenceBusiness Wire
- Aldeyra Therapeutics Selected to Present at the Disruptive Innovations Symposium during the OSN New York Retina 2024 MeetingBusiness Wire
- Aldeyra Therapeutics resubmits new drug application for treatment of dry eye disease [Seeking Alpha]Seeking Alpha
- Aldeyra Therapeutics Resubmits Reproxalap New Drug Application for the Treatment of Dry Eye DiseaseBusiness Wire
- Aldeyra Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment ConferenceBusiness Wire
ALDX
Earnings
- 11/7/24 - In-Line
ALDX
Sec Filings
- 11/14/24 - Form SC
- 11/7/24 - Form 10-Q
- 10/21/24 - Form 4
- ALDX's page on the SEC website